Find a Clinical Trial | American Lung Association

LUNG STAAR

The purpose of this research is to offer patients with centrally located early-stage non-small cell lung cancer (NSCLC) who are NOT candidates for surgery the opportunity to receive stereotactic body radiation therapy (SBRT).

Miranda

Tozorakimab is hypothesized to have a beneficial effect in patients with COPD by reducing the frequency and severity of COPD exacerbations and improving COPD symptoms and quality of life.

MIST

This is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of AP01 versus placebo on top of standard of care in participants with PPF over 52 weeks. Up to 300 eligible participants will be randomized to 1 of 3 treatment arms: AP01 high dose, AP01 low dose, or placebo.

Optimizing self-management COPD treatment through the American Lung Association Helpline

The current study will test the feasibility of using an engineering-inspired study design to identify effective COPD self-management treatment components.

PALOMA-2

A Study of Amivantamab in Participants with Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

PALOMA-3

A Study of Lazertinib and Amivantamab in Participants with Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer.

Phase 2, Open-Label, Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 subjects with KRASG12C mutant NSCLC that have not been exposed to prior therapy with KRASG12C inhibitors and/or SHP2 inhibitors.

Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis

The purpose of this study is to compare the effectiveness and the safety of sarilumab in patients with glucocorticoid-dependent sarcoidosis.

Study of BDTX-1535 in Participants With Glioblastoma or Non-Small Cell Lung Cancer

This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of BDTX-1535 in patients with GBM or NSCLC harboring sensitive EGFR alterations and who have disease progression following standard of care

TCR001-201

To evaluate the objective response rate (ORR) (RECIST and iRECIST criteria) of subjects with solid cancers who receive TCR-T cell drug product, define the incidence of dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of T-Cell Receptor T cells, and evaluate the feasibility of TCR-T cell drug product manufacturing.

Next